tobramycin
treatment
pseudomonas
aeruginosa
infections
cystic
fibrosis
tobramycin
treatment
chronic
pulmonary
infections
caused
pseudomonas
aeruginosa
children
cystic
fibrosis
evaluated
initially
patients
received
recommended
dose
mg
hours
dose
increased
mg
hours
approximately
mg
kg
hours
higher
dosage
administered
intramuscularly
patients
eight
received
additional
therapy
aerosol
containing
tobramycin
therapy
possible
eradicate
ps
aeruginosa
respiratory
tract
patients
discontinuing
therapy
ps
aeruginosa
occurred
patients
within
one
month
patients
showed
clinical
improvement
relation
therapy
toxic
allergic
side
effects
observed
